Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either Tirofiban or placebo during angioplasty in the RESTORE trial

Journal of the American College of Cardiology

Volumn 32, Issue 1, 1998, Pages 28-34

  Gibson, C Michael ^f   Goel, Mukesh ^a   Cohen, David J ^b   Piana, Robert N ^c   Deckelbaum, Lawrence I ^d   Harris, Katherine E ^d   King III, Spencer B ^e  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e EMORY UNIVERSITY HOSPITAL   (United States)

^f ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TIROFIBAN;

ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; ATHERECTOMY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0001859684     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00192-2     Document Type: Article

References (32)

1. Harrington R.A. Antithrombotic therapy during percutaneous coronary intervention. J Thr Thrombolysis. 2:1995;21-28.
2. Boston D.R., Malouf A., Barry W.H. Management of intracoronary thrombosis complicating percutaneous transluminal coronary angioplasty. Clin Cardiol. 19:1996;536-542.
3. De Feyter P.J., van den Brand M., Jaarman G., van Domburg R., Serruys P.W., Suryapranata H. Acute coronary occlusion during and after percutaneous transluminal coronary angioplasty. Circulation. 83:1991;927-936.
4. Lincoff A.M., Popma J.J., Ellis S.G., Hacker J.A., Topol E.J. Abrupt vessel closure complicating coronary angioplasty clinical, angiographic and therapeutic profile . J Am Coll Cardiol. 19:1992;926-935.
5. Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Eng J Med. 330:1994;956-961.
6. Théroux P., Kouz S., Roy L., et al. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. Circulation. 94:1996;899-905.
7. Willerson J.T. Inhibitors of platelet glycoprotein IIb/IIIa receptors will they be useful when given chronically? Circulation. 94:1996;866-868.
8. Weitz J.I., Califf R.M., Ginsberg J.S., et al. New antithrombotics. Chest. 108:(Suppl):1995;471S-485S.
9. Ezratty A.M., Loscalzo J. New approaches to antiplatelet therapy. Blood Coagul Fibrinolysis. 2:1991;317-327.
10. Coller B.S. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation. 92:1995;2373-2380.
11. Lefkovits J., Topol E.J. Platelet glycoprotein IIb/IIIa receptor inhibitors in ischemic heart disease. Curr Opin Cardiol. 10:1995;420-426.
12. Tcheng J.E. Enhancing safety and outcomes with the newer antithrombotic and antiplatelet agents. Am Heart J. 130:1995;673-679.
13. Frishman W.H., Burns B., Bulent A., et al. Novel antiplatelet therapies for treatment of patients with ischemic heart disease inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor . Am Heart J. 130:1995;877-892.
14. Ellis S.G., Bates E.R., Schaible T., et al. Prospects for the use of antagonists to the platelet glycoprotein IIb/IIa receptor to prevent post-angioplasty restenosis and thrombosis. J Am Coll Cardiol. 17:(Suppl B):1991;89B-95B.
15. Topol EJ, Califf RM, Weisman HF, et al., on behalf of the EPIC Investigators. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994;343:881-6.
16. Tcheng J.G. Glycoprotein IIb/IIIa receptor inhibitors putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective . Am J Cardiol. 78:(Suppl 3A):1996;35A-40A.
17. Gates E.R., McGillem M.J., Mickelson J.K., et al. A monoclonal antibody against the platelet glycoprotein IIb/IIIa receptor complex prevents platelet aggregation and thrombosis in a canine model of coronary angioplasty. Circulation. 84:1991;2463-2469.
18. Egbertson M.S., Chang C.T.C., Duggan M.E., et al. Non-peptide fibrinogen receptor antagonists optimization of a tyrosine template as a mimic for Arg-Gly-Asp . J Med Chem. 37:1994;2537-2551.
19. Hartman G.D. Tirofiban hydrochloride platelet antiaggregatory GP IIb/IIIa receptor antagonist . Drugs Future. 20:1995;897-901.
20. Peerlinck K., DeLepeleire I., Goldberg M., et al. MK-383 (L-700, 462), a selective non-peptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation. 88:1993;1512-1517.
21. Lynch J.J., Cook J.J., Sitko G.R., et al. Nonpeptide glycoprotein IIb/IIIa inhibitors. Antithrombotic effects of MK-0383. J Pharmacol Exp Ther. 272:1995;20-32.
22. Kereiakes M., Kleiman S., Ambrose A., et al. Randomized, double-blind, placebo-controlled dose ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol. 27:1996;536-542.
23. The effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 96:1997;1445-1453.
24. Gibson C.M., Sandor T., Stone P.H., Pasternak R.C., Rosner B., Sacks F.M. Quantitative angiographic and statistical methods to assess serial changes in coronary diameter and implications for atherosclerosis regression trials. Am J Cardiol. 69:1992;1286-1290.
25. Reiber J.H.C., Surreys P.W., Barth J.D. Quantitative coronary angiography. Marcus M.L., Schelbert H.R., Skorton D.J., Wolf G.L. Cardiac Imaging. 1991;211-280 WB Saunders, Philadelphia.
26. The Thrombolysis in Myocardial Infarction (TIMI) trial phase I findings . N Engl J Med. 312:1985;932-936.
27. Gibson C.M., Cannon C.P., Daley W.L., et al. The TIMI frame count a quantitative method of assessing coronary artery flow . Circulation. 93:1996;879-888.
28. Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) trial . Circulation. 87:1993;38-52.
29. SAS/STAT User's Guide. 1990;1075-1126 SAS Institute, Cary (NC).
30. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina the CAPTURE study . Lancet. 349:1997;1429-1435.
31. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Eng J Med. 336:1997;1689-1696.
32. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention IMPACT-II . Lancet. 349:1997;1422-1428.